Quantcast

Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S.

March 2, 2009

No. 1 Selling Prefilled Insulin Pen in the World Available with Levemir(R), NovoLog(R) and NovoLog(R) Mix 70/30

PRINCETON, N.J., March 2 /PRNewswire-FirstCall/ — Novo Nordisk has redesigned FlexPen(R), the number one selling pre-filled insulin pen in the world(1), to allow diabetes patients to use less force when pushing the button to inject their insulin and easily identify their insulin with prominent color branding. FlexPen(R) is only available with Novo Nordisk insulin products, Levemir(R) (insulin detemir [rDNA origin] injection), NovoLog(R) (insulin aspart [rDNA origin] injection) and NovoLog(R) Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]).

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/novonordisk/37286/

Building on more than 25 years of research and development on insulin delivery devices, the improved FlexPen(R) requires 30 percent less injection force (the amount of pressure needed to press the button to inject the insulin) than the original FlexPen(R).(2) In a laboratory study the improved Levemir(R) FlexPen(R) had a significantly lower injection force compared to Lantus SoloSTAR(R).(3)

The improved FlexPen(R) has enhanced color branding, with color-identifiable cartridge holders for both the Levemir(R) FlexPen(R) and NovoLog(R) FlexPen(R). When the cap is removed, the entire portion under the cap is colored (green for Levemir(R), orange for NovoLog(R) and clear for NovoLog(R) Mix 70/30). Packaging for both sample and trade products has been redesigned to match the colors of the FlexPen(R). The improvements can help patients, HCPs, and pharmacists easily identify their insulin.

Similar to the original FlexPen(R), the improved FlexPen(R) allows users to set an appropriate dose, and does not allow a dose larger than the amount of insulin remaining in the pen. It also permits dose corrections without loss of insulin, and provides doses in one-unit increments up to 60 units per injection (each pen contains 300 units in total). The dose scale of the improved FlexPen(R) automatically returns to zero after each injection to allow visual confirmation of dose delivery. Like the original FlexPen(R), once in use, FlexPen(R) does not require refrigeration (below 86° F) for up to 42 days if used with Levemir(R), for up to 28 days if used with NovoLog(R) and for up to 14 days if used with NovoLog(R) Mix 70/30.

“Although insulin pens are underused in the U.S. versus other countries, the continued innovation we’ve seen with FlexPen(R) may help meet the needs of people living with the challenges of this disease,” said Bruce Bode, MD, FACE, Atlanta Diabetes Associates. Being easy to learn, easy to use, and easy to teach, the improved FlexPen(R) is a convenient option for taking insulin.

The improved FlexPen(R) is now available nationwide. FlexPen(R) is covered on more than 90 percent of insurance plans. For more information about FlexPen(R), visit http://www.novonordiskcare.com/flexpen/. The prescribing information for FlexPen(R) is available by contacting Novo Nordisk or visiting novonordisk-us.com.

About Levemir(R) (insulin detemir [rDNA origin] injection)

Levemir(R) (insulin detemir [rDNA] injection) is a man-made long-acting insulin that is used to control high blood sugar in adults and children with diabetes mellitus.

Important Safety Information

Check your blood sugar levels. Ask your health care provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take Levemir(R).

Do not change the type of insulin you use unless told to do so by your health care provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.

Never mix Levemir(R) with other insulin products or use in an insulin pump.

Do not take Levemir(R) if your blood sugar is too low (hypoglycemia) or if you are allergic to anything in Levemir(R). If you take too much Levemir(R) your blood sugar may fall too low.

Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your Levemir(R) dose may change if you take other medicines.

The most common side effect of insulin therapy, including Levemir(R) is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site (like redness, swelling and itching), and allergic reactions. Get medical help right away if you experience signs of serious allergic reaction such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.

About NovoLog(R) (insulin aspart [rDNA origin] injection)

Levemir(R) (insulin detemir [rDNA] injection) is a man-made long-acting insulin that is used to control high blood sugar in adults and children with diabetes mellitus.

Important Safety Information

Check your blood sugar levels. Ask your health care provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take Levemir(R).

Do not change the type of insulin you use unless told to do so by your health care provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.

Never mix Levemir(R) with other insulin products or use in an insulin pump.

Do not take Levemir(R) if your blood sugar is too low (hypoglycemia) or if you are allergic to anything in Levemir(R). If you take too much Levemir(R) your blood sugar may fall too low.

Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your Levemir(R) dose may change if you take other medicines.

The most common side effect of insulin therapy, including Levemir(R) is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site (like redness, swelling and itching), and allergic reactions. Get medical help right away if you experience signs of serious allergic reaction such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.

About NovoLog(R) (insulin aspart [rDNA origin] injection)

NovoLog(R) is a man-made insulin that is used to control high blood sugar in adults and children with diabetes mellitus.

Important Safety Information

NovoLog(R) is a fast-acting insulin. You should eat a meal within 5 to 10 minutes after using NovoLog(R) to avoid low blood sugar. Do not inject NovoLog(R) if you do not plan to eat right after using NovoLog(R). Check your blood sugar levels. Ask your health care provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take NovoLog(R).

Do not change the type of insulin you use unless told to do so by your health care provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.

Do not mix NovoLog(R) with any other insulins when used in a pump or with any insulins other than NPH when used with injections by syringe.

Do not take NovoLog(R) if your blood sugar is too low (hypoglycemia) or if you are allergic to anything in NovoLog(R). If you take too much NovoLog(R) your blood sugar may fall too low.

Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your NovoLog(R) dose may change if you take other medicines.

The most common side effect of insulin therapy, including NovoLog(R) is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site (like redness, swelling, and itching) and allergic reactions. Get medical help right away if you experience signs of serious allergic reaction such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.

About NovoLog(R) Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])

NovoLog(R) Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is a man-made insulin that is used to control high blood sugar in adults with diabetes mellitus.

Important Safety Information

NovoLog(R) Mix 70/30 is a pre-mixed insulin. You should eat a meal within 15 minutes after using NovoLog(R) Mix 70/30 to avoid low blood sugar. Do not inject NovoLog(R) Mix 70/30 if you are not planning to eat within 15 minutes. Check your blood glucose regularly. Ask your health care provider what your blood sugars should be and when you should check your blood sugar levels. Alcohol, including beer and wine, may affect your blood sugar when you take NovoLog(R) Mix 70/30.

Do not change the type of insulin you use unless told to do so by your health care provider. The amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin.

Never mix NovoLog(R) Mix 70/30 with other insulin products or use it in an insulin pump.

Do not use NovoLog(R) Mix 70/30 if your blood glucose is too low (hypoglycemia) or if you are allergic to anything in NovoLog(R) Mix 70/30. If you take too much NovoLog(R) Mix 70/30 your blood sugar may fall too low.

Tell your health care provider about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. Your NovoLog(R) Mix 70/30 dose may change if you take other medicines.

The most common side effect of insulin therapy, including NovoLog(R) Mix 70/30, is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site (like redness, swelling and itching), and allergic reactions. Get medical help right away if you experience signs of serious allergic reaction such as body rash, trouble with your breathing, fast heartbeat, or sweating. Ask your doctor or pharmacist for further information.

*Lantus SoloStar(R) is a disposable insulin delivery device developed, manufactured and marketed by sanofi-aventis.

Lantus(R), SoloSTAR(R) is a registered trademark of sanofi-aventis U.S., LLC. FlexPen(R), Levemir(R), and NovoLog(R) are registered trademarks of Novo Nordisk A/S.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk’s business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For global information, visit novonordisk.com; for United States information, visit www.novonordisk-us.com.

(1) IMS Health Inc. IMS MIDAS (12 months ending September 2008).

(2) Pfutzner A et al. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin 2008; 24(9):2545-2549.

(3) Rissler J et al. Evaluation of the injection force dynamics of a modified prefilled insulin pen. Expert Opin. Pharmacother 2008; 9(13): 2217-2222.

SOURCE Novo Nordisk


Source: newswire



comments powered by Disqus